To describe the occurrence of baseline co-morbidity in subjects with active rheumatoid arthritis (RA) starting treatment with biologic agents. Such data are necessary to interpret the reported occurrence of adverse events following therapy.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial joints and other tissues. It is also considered a systemic disease and as such is associated with an increase in mortality predominantly from non-arthritis related causes (1) (2) (3) . Although there have been few studies, RA subjects also report a high level of associated comorbidity. Thus, Berkanovic et al found that 54% of 288 randomly selected patients with RA reported at least one additional chronic disease (4). Gabriel et al reported that almost 60% of an RA cohort (n=450) had at least one other medical condition compared with only 49% of age and sex matched non-RA controls (5) . The majority of these conditions were represented by cardiovascular disease (CVD), malignancy, peptic ulcer disease (PUD), and chronic lung disease. These increases in mortality and morbidity may be related to the RA itself, shared risk factors between RA and the associated co-morbidities or from the adverse effects of anti-rheumatic therapies.
The introduction of biologic drugs into the treatment armamentarium has revolutionised the modern management of RA. There is, however, a theoretical concern that this particular group of therapies may increase the risk of various morbidities. Reassuringly, though, there was no increase in serious adverse events in patients receiving biologic therapies in the so-called 'pivotal' randomised controlled trials (RCT's) compared with placebo. However, it is possible that due to strict entry criteria, such RCT's selectively excluded patients with significant co-morbidity risk. Therefore, it is difficult to use these data to draw any firm conclusions on the safety of biologic therapies in patients who receive the drugs during routine practice.
There remains limited data on the safety of these agents in routine use. There have been reports of a possible increase of certain serious adverse events, including serious infections (6) (7) (8) , tuberculosis (9,10), demyelination (11), congestive heart failure (12) and malignancies (13) . Most of these data have been in the form of spontaneous adverse event reports. Before, however, events can be attributed to these new treatments, it is important to ascertain the level of baseline coexistent disease among a treated cohort. Patients who are selected for biologic therapy are likely to represent those with the most severe disease who may already have high level of comorbidity. This leads to the specific question: What is the level of comorbidity among patients starting biologic therapy during routine clinical use? To address this question, we set out to identify the prevalence and types of comorbidity in a large national register of RA patients receiving biologic therapy during routine practice in the United Kingdom (UK).
METHODS

Study Design
As described elsewhere (14) the British Society for Rheumatology Biologics Register (BSRBR) is a national prospective observational study, established in October 2001, to carefully monitor the long-term effects of biologic therapy. Data are gathered in a standardised format on all patients aged 16 years or older starting biologic therapy for a rheumatic disease throughout the UK. Unlike an RCT, the decision to start or change DMARD and biologic therapy was solely at the discretion of the treating rheumatologist, although national guidelines currently limit the use of biologic therapies to those patients with active RA (defined as 28-joint count disease activity score (DAS28) >5.1 despite previous therapy with at least 2 DMARD's one of which should have been methotrexate (15) ). This current analysis is limited to patients who fulfilled the 1987 ACR Classification criteria for RA (16) and were registered with the BSRBR prior to October 1, 2004.
Baseline information
Baseline information on all patients was obtained from the treating rheumatologist via standard questionnaires. Information included demographics, disease characteristics, and past and present anti-rheumatic therapies. In addition, all the necessary clinical and laboratory data to calculate a DAS28 (17) were collected at the time the patient was starting their new therapy. Patients were also asked to complete a Health Assessment Questionnaire (HAQ) (18) and the SF-36 (19)).
Identification of Comorbidity
Comorbidity was assessed, at the time of starting therapy, using a pre-specified list of coexisting conditions on the baseline questionnaire (Table 1 ). This data was obtained from the patient's medical records. In addition, physicians were asked to supply a complete list of the patient's current medications. This list was used to identify any further comorbid conditions, for example the prescription of thyroxine was considered to represent underlying hypothyroidism. It was also used to confirm other diagnoses. For example, patients were only considered to have a diagnosis of hypertension if they were receiving antihypertensive therapy. Comorbidities were recorded as present (ever) or absent. Further details on individual comorbid disease severity were not collected. For each patient, the presence of any comorbidity and the number of comorbidities was determined.
Ethical Approval
Ethical approval for this study was obtained from the UK National Health Service Central Office for Research Ethics Committee.
RESULTS
Biologic Cohort
In total, 7818 persons with RA who had started a biologic drug had been registered with the BSRBR to October 1, 2004. The majority of the patients were receiving either etanercept (n=3302) or infliximab (n=3332). An additional 1059 subjects were receiving adalimumab and 132 were receiving anakinra. Baseline characteristics are presented in Table 2 . Sixty-nine percent were receiving a concurrent DMARD (Table  3) , 49% were receiving corticosteroids, and 65% were receiving non-steroidal antiinflammatory drugs (NSAIDs).
Co-morbidity
In all 58% of patients starting a biologic therapy reported at least one, and 25% reported more than one, comorbid condition (Error! Reference source not found.). The most common comorbid conditions identified (Table 4) was cardiovascular disease, including hypertension (22%), and ischaemic heart disease (6%). Five percent of patients were reported to be diabetic. There was also a high prevalence of pulmonary disease including asthma (10%) and chronic obstructive pulmonary disease (COPD) (5%). Of specific interest, 152 (2%) patients were reported to have a past exposure or infection with Mycobacterium tuberculosis (TB). One fifth of the cohort were reported to have depression. Previous malignancy was uncommon ( n=152, 3%) the most frequent being basal cell carcinomas (n=73), breast cancer (n=47) and malignancy of the female reproductive tract (n=35). Two patients were reported to have had a history of lymphoproliferative disease.
.
Discussion
The burden of comorbid diseases was high among this large national cohort of patients starting biologic therapy, with 58% having at least one comorbid condition. The most frequent comorbid conditions were cardiovascular and respiratory disease and depression. Interpretation of the occurrence of morbidity diagnosed following the start of biologic therapy needs to take into account this baseline burden.
The ascertainment of the comorbidities was based on the patient clinical interview, documented co-morbidity in the rheumatological case records and the nature of current therapy. Although this approach to gathering co-morbidity data in large sacle studies is widespread, there has to be a level of uncertainty in the accuracy of these both in terms of false positives and negatives. The interpretation of the different comorbidities needs to take this into account, Thus the data on current treated hypertension and diabetes are likely to substantially more accurate than, for example, the self or physician reported previous diagnosis of peptic ulcer. However, the cohort was a nationally recruited one and thus there were unlikely to be biases due to the selection of specific groups of patients or rheumatological centres.
One interesting issue is whether the co-morbidity in this cohort represents selection factors in those eligible for therapy or whether it is an indication of the co-morbidity levels in a severe RA patient population. Indeed in order to interpret data on the incidence of new adverse events in the anti-TNF treated group, the BSRBR is also concurrently recruiting, as a comparison group from over 20 major rheumatological centres, a nationwide cohort of RA patients with active disease who have started on a new non-biologic DMARD within the previous 6 months. It was also possible therefore to use that dataset to address whether there are major differences between anti-TNF and standard DMARD treated patients in their co-morbidity. Baseline data is collected in an identical fashion on these patients. By October 1, 2004, 969 patients had been recruited to this cohort. Although they have a shorter mean disease duration (9 years versus 14 years), they were similar in age (mean 59 years) and gender (70% female). The level of baseline co-morbidity in this cohort was, however, similar to that in our biologic cohort (both 62%). Again, the most frequent conditions were hypertension (25%), asthma (15%) and depression (18%). There was not a higher rate of previous tuberculosis infection (2%) although there was a slightly higher rate of previous malignancy (5%), which would not be unexpected given the contraindications for anti-TNF therapies. Thus these data would suggest that the high baseline co-morbidity in the anti-TNF treated cohort reflects that in a population of RA patients under current active therapy
The strengths of the BSRBR lie in its size and inclusive nature. In the UK, mandatory registration of all patients (with consent) with the BSRBR forms part of the national guidelines for the use of these agents in RA. Therefore, it is likely that the patients in this study are a true reflection of all patients with RA receiving biologic therapy in the UK. The prevalence of comorbidity does not appear to be higher than that reported prior to the widespread use of anti-TNF therapies (4, 5, 20) . Although it is difficult to compare directly across studies, due both to the lack of standardisation in comorbidity assessment between studies and differences between the cohorts in terms of disease duration and severity, the results suggest that physicians are not avoiding these drugs in patients with co-morbid disease.
The findings of this study confirm that the baseline rate of coexistent conditions among patients starting biologic therapy is high. As a consequence, reports, for example, of new episode of co-morbidity such as an exacerbation of congestive heart failure following the use of anti-TNFα therapy must take into account the high baseline rate of cardiovascular disease in this population. Similarly, a high rate of pulmonary disease, including COPD and asthma prior to the start of biologic therapy may already place these patients at an increased risk of respiratory infection, regardless of the use of biologic therapy. The occurrence of adverse events in RA patients on biologic therapy must be interpreted in the light of these findings of a high background level of co-morbidity Your manuscript should contain the following statement: "The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://ard.bmjjournals.com/misc/ifora/licenceform.shtml).
